ABBISKO CAYMAN LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.28 HKD | +4.79% |
|
+13.10% | -10.14% |
| Apr. 25 | Abbisko Cayman's Liver Cancer Drug Gets US FDA Orphan Drug Designation | MT |
| Apr. 24 | Abbisko Cayman Limited Announces Resignation of Tian Huimin as Joint Company Secretary | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 5,209 | 1,990 | 1,969 | 1,773 | - | - |
| Enterprise Value (EV) 1 | 2,718 | -223.7 | -2.488 | -155.2 | 387.7 | 1,071 |
| P/E ratio | -0.96 x | -3.54 x | -4.95 x | -3.7 x | -3.23 x | -3.13 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 230 x | - | 103 x | 10.6 x | 6.96 x | 5.7 x |
| EV / Revenue | 120 x | - | -0.13 x | -0.92 x | 1.52 x | 3.44 x |
| EV / EBITDA | -8.6 x | 0.46 x | 0.01 x | 3.22 x | -0.64 x | -1.55 x |
| EV / FCF | -15.2 x | 0.62 x | 0.01 x | 0.88 x | -32.3 x | -3.32 x |
| FCF Yield | -6.58% | 162% | 18,260% | 113% | -3.1% | -30.2% |
| Price to Book | 2.05 x | 0.75 x | 1.08 x | 1.1 x | 1.73 x | 3.3 x |
| Nbr of stocks (in thousands) | 702,578 | 701,774 | 593,518 | 583,989 | - | - |
| Reference price 2 | 7.415 | 2.835 | 3.318 | 3.036 | 3.036 | 3.036 |
| Announcement Date | 3/18/22 | 3/15/23 | 3/12/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 22.68 | - | 19.06 | 168 | 254.7 | 311.2 |
| EBITDA 1 | -316.2 | -481.4 | -492.7 | -48.14 | -608.6 | -689.5 |
| EBIT 1 | -328.2 | -497.2 | -511.1 | -54.67 | -227.3 | -543.2 |
| Operating Margin | -1,447.05% | - | -2,681.41% | -32.54% | -89.21% | -174.57% |
| Earnings before Tax (EBT) 1 | -1,810 | -495.6 | -431.6 | -50 | - | - |
| Net income 1 | -1,810 | -495.6 | -431.6 | -517.5 | -785.3 | -794.7 |
| Net margin | -7,979.87% | - | -2,264.34% | -308.02% | -308.28% | -255.35% |
| EPS 2 | -7.710 | -0.8000 | -0.6700 | -0.8200 | -0.9400 | -0.9700 |
| Free Cash Flow 1 | -178.8 | -363.5 | -454.3 | -176 | -12 | -323 |
| FCF margin | -788.09% | - | -2,383.68% | -104.76% | -4.71% | -103.79% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 3/18/22 | 3/15/23 | 3/12/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 19.06 | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - |
| Net income | - | - | - | - | -223 | -306.4 | -390 |
| Net margin | - | - | - | - | - | - | - |
| EPS | - | - | - | - | -0.3500 | -0.3700 | -0.4500 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 8/22/22 | 8/22/22 | 3/15/23 | 8/15/23 | 3/12/24 | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 2,492 | 2,213 | 1,971 | 1,928 | 1,385 | 702 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -179 | -364 | -454 | -176 | -12 | -323 |
| ROE (net income / shareholders' equity) | -253% | -20.3% | -19.9% | -1.9% | -34.7% | -62.7% |
| ROA (Net income/ Total Assets) | -109% | -20.6% | -19.4% | -2.3% | - | - |
| Assets 1 | 1,660 | 2,402 | 2,225 | 22,499 | - | - |
| Book Value Per Share 2 | 3.610 | 3.780 | 3.060 | 2.770 | 1.760 | 0.9200 |
| Cash Flow per Share 2 | -0.7200 | -0.5500 | -0.6900 | -0.2400 | - | - |
| Capex 1 | 9.01 | 19.6 | - | 25 | 25 | 25 |
| Capex / Sales | 39.74% | - | - | 14.88% | 9.81% | 8.03% |
| Announcement Date | 3/18/22 | 3/15/23 | 3/12/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.036
CNY
Average target price
7.572
CNY
Spread / Average Target
+149.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.14% | 245M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 2256 Stock
- Financials Abbisko Cayman Limited
